NCT02659475已完成2 期
Open-label Phentermine/Topiramate Extended Release (PHEN/TPM ER; Qsymia®) in Ten Subjects With Overweight or Obesity and DSM-V Binge Eating Disorder (BED)
Lindner Center of HOPE1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2015年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- change in weight
研究概览
简要总结
The goal of this project is to evaluate the effectiveness and tolerability of the novel weight management medication PHEN/TPM ER (Qsymia®)along with nutritional and lifestyle modification counseling in the treatment of binge eating disorder (BED) in overweight or obese individuals.
详细描述
This is an exploratory open-label trial of PHEN/TPM ER (Qsymia®) in BED. It is hypothesized that PHEN/TPM ER (Qsymia®) will be an effective, safe, and well tolerated treatment for BED and propose to conduct a 1-site, 12-week, open-label, flexible dose study of PHEN/TPM ER (Qsymia®) in 10 outpatients, ages 18 through 65 years, with BED. It is also hypothesized that PHEN/TPM ER (Qsymia®) will reduce weight and binge eating behavior, and will be well tolerated. The primary objective is to show that PHEN/TPM ER (Qsymia®) along with nutritional and lifestyle modification counseling is effective in reducing weight in overweight or obese patients with BED. Secondary objectives are to show that PHEN/TPM ER (Qsymia®) is effective in reducing frequency of binge eating episodes and associated eating psychopathology and is safe and well tolerated in patients with BED.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women, ages of 18- 65 years, inclusive.
- •Subjects will meet DSM-5 criteria for a diagnosis of BED. These are:
- •A. Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following:
- •Eating, in a discrete period of time (e.g., within a 2 hour period) an amount of food that is definitely larger than most people would eat in a similar period of time under similar conditions, and
- •Sense of lack of control over the eating (e.g., a feeling that one cannot stop eating or control what or how much one is eating)
- •B. The binge eating episodes are associated with at least three of the following:
- •eating much more rapidly than normal
- •eating until uncomfortably full
- •eating large amounts of food when not feeling physically hungry
- •eating alone because of being embarrassed by how much one is eating
- •feeling disgusted with oneself, depressed, or feeling very guilty after overeating
- •C. Marked distress regarding binge eating is present
- •D. The binge eating occurs, on average, at least once a week for 3 months
- •E. The binge eating is not associated with the recurrent use of inappropriate compensatory behavior as in bulimia nervosa and does not occur exclusively during the course of bulimia nervosa or anorexia nervosa
- •Subjects will be obese (defined as a BMI ≥ 30 mg/kg2) or overweight (defined as BMI ≥ 27 kg/m2 or greater) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or dyslipidemia.
- •Subjects in treatment for a weight-related comorbidity (hypertension, type 2 diabetes mellitus, and/or dyslipidemia), must be on a stable medication regimen, defined as being on current dose of medication for at least 3 months prior to study enrollment.
排除标准
- •Current bulimia nervosa or anorexia nervosa.
- •Women who are pregnant, lactating, or of childbearing potential who are not using adequate contraceptive measures. The following are considered to be adequate methods of birth control:
- •Intrauterine device (IUD);
- •Barrier protection;
- •A contraceptive implantation system (Norplant);
- •Oral contraceptive pills;
- •A surgically sterile partner; and
- •Abstinence. Women who are >2years post-menopausal or surgically-sterile are not considered of childbearing potential. All female subjects will have a negative pregnancy test prior to randomization.
- •Subjects who are displaying clinically significant suicidality operationalized as a score ≥ 2 on item 9 of the Beck Depression Inventory (BDI) (21), or suicidal ideation on the Columbia-Suicide Severity Scale (C-SSRS) (22), or homicidality.
- •Subjects who are receiving a psychological (e.g., supportive psychotherapy, cognitive behavior therapy, interpersonal therapy) or weight loss (e.g., Weight Watchers) intervention for BED or weight management that was begun within the 3 months before study entry. Subjects who are receiving psychotherapy that was initiated prior to 3 months of the beginning of the study will be allowed to continue to receive their psychotherapy during the trial only if they agree to not make any changes in the frequency or nature of their psychotherapy during the course of the drug trial.
- •A DSM-5 diagnosis of a substance-related or addictive disorder (except a tobacco-related disorder) within the 6 months prior to enrollment.
- •A lifetime DSM-5 history of psychosis, mania or hypomania, or dementia.
- •History of any psychiatric disorder which might interfere with a diagnostic assessment, treatment, or compliance.
- •Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease. Subjects should be biochemically euthyroid to enter the study.
- •Have a history of a structural cardiac abnormality, valvular cardiac disease, cardiomyopathy, serious heart rhythm abnormality, coronary artery disease, stroke, or other serious cardiovascular problem.
- •History of seizure disorder, including clinically-significant febrile seizures in childhood.
- •Subjects with glaucoma or hyperthyroidism.
- •Have an ECG with significant arrhythmias or conduction abnormalities, which in the opinion of the physician investigator preclude study participation.
- •Have clinically relevant abnormal laboratory results.
- •Subjects requiring treatment with any drug which might interact adversely with or obscure the action of the study medication. This includes anti-obesity drugs, psychostimulants, wake-promoting agents, drugs with serotonergic properties, antidepressants, and antipsychotics.
- •Subjects who have received any psychotropic medications (other than hypnotics) within four weeks prior to randomization, including monoamine oxidase inhibitors, tricyclics, selective serotonin reuptake inhibitors, antipsychotics, mood stabilizers, or psychostimulants.
- •Subjects who have received investigational medications or depot neuroleptics within three months prior to randomization.
- •Subjects who have a known allergy to PHEN/TPM ER (Qsymia®) or its constituents.
- •Subjects with a urine drug screen positive for a drug that, in the opinion of the investigator, is being abused.
研究组 & 干预措施
PHEN/TPM ER (Qsymia®)
Experimental
PHEN/TPM ER (Qsymia®)
干预措施: PHEN/TPM ER (Qsymia®) (Drug)
结局指标
主要结局
change in weight
时间窗: from baseline visit (week 0) to final visit or early termination
Weight will be measured at all study visits - screen, baseline (week 0), and weeks 2, 4, 6, 8, 10. 12
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated CirrhosisCompensated CirrhosisPrimary Sclerosing CholangitisNCT04060147Gilead Sciences11
招募中
4 期
An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early EveningAttention-deficit/Hyperactivity DisorderNCT06577779NYU Langone Health30
已完成
3 期
PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeNarcolepsySleep Apnea, ObstructiveNCT00107848Cephalon280
已完成
4 期
Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOSADHDNCT00586573Massachusetts General Hospital34
已完成
1 期
Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid TumoursSolid Tumor, AdultNCT03008018Karus Therapeutics Limited20